Collegium Pharmaceutical Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Für Collegium Pharmaceutical wird ein Gewinn- und Umsatzwachstum von 41.9% bzw. 2.7% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 27.4% pro Jahr steigen soll.
Wichtige Informationen
41.9%
Wachstumsrate der Gewinne
27.37%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 14.4% |
| Wachstumsrate der Einnahmen | 2.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 13 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analyseartikel • May 14
Statutory Profit Doesn't Reflect How Good Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are
The subdued stock price reaction suggests that Collegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) strong earnings didn't...
Narrativ-Update • Apr 25
COLL: Affordable Medicines Theme Will Support 2026 Earnings Conviction And Upside Potential
Analysts have raised their price target on Collegium Pharmaceutical by $3, citing updated assumptions about revenue growth, profit margin expectations, and a slightly revised P/E multiple as the main factors behind the change. Analyst Commentary Bullish Takeaways Bullish analysts view the $3 price target increase as support for their view that updated revenue assumptions still justify a premium to prior expectations.Narrativ-Update • Apr 11
COLL: Affordable Medicines Theme Will Support 2026 Earnings Strength And Risk Reward Upside
Analysts have raised their price target on Collegium Pharmaceutical by $3 to reflect updated assumptions around valuation inputs, while keeping fair value, discount rate, revenue growth, profit margin, and future P/E estimates essentially unchanged. Analyst Commentary Bullish Takeaways Bullish analysts view the $3 price target increase as confirmation that their core valuation framework on fair value, discount rate, and P/E assumptions still holds, which can signal confidence in the company’s ability to execute on its current plan.Narrativ-Update • Mar 25
COLL: Affordable Medicines Theme Will Support 2026 Margin Resilience And Earnings Strength
Analysts have slightly increased their consolidated price target for Collegium Pharmaceutical by about $0.33 per share, citing updated assumptions for modest revenue growth, higher profit margins, and a lower future P/E multiple that reflect recent Street research from Truist and Barclays. Analyst Commentary Recent research updates on Collegium Pharmaceutical show a mix of optimism and caution as analysts refresh their models around the company’s 2026 outlook, valuation framework, and earnings power.Seeking Alpha • Mar 20
Collegium Pharmaceutical: Another M&A Episode Adds To An Intriguing Case
Summary Collegium Pharmaceutical announced a $650M cash acquisition of AZSTARYS, aiming to boost ADHD portfolio synergies and pro forma sales. COLL expects the deal to add $50M in 2026H2 revenue and targets $50M annual run-rate synergies, financed with cash and a $300M term loan. Despite strong adjusted margins and earnings, Collegium trades at low multiples due to patent expiry concerns and rapid drug portfolio runoff. With net leverage rising above $1B post-deal and some ambiguity on new asset contributions, conviction remains challenged but the valuation appears undemanding. Read the full article on Seeking AlphaNarrativ-Update • Mar 10
COLL: Affordable Medicines Theme Will Support 2026 Margin Expansion And Higher Earnings Power
Narrative Update on Collegium Pharmaceutical The analyst price target for Collegium Pharmaceutical has edged up by about $0.17, supported by recent Street research that combines slightly softer revenue growth assumptions with higher expected profit margins and a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Collegium Pharmaceutical reflects a mix of optimism and caution around the updated price targets and longer term outlook, with views centering on how well the company can execute against its 2026 framework and how that is captured in current valuation multiples.Narrativ-Update • Feb 24
COLL: Affordable Medicines Theme Will Support 2026 Earnings Visibility And Upside P/E Rerating
Analysts raised their fair value estimate for Collegium Pharmaceutical by about $0.50 per share to $53.67, reflecting recent shifts in Street price targets and updated views on long term revenue trends, margins, and the appropriate future P/E multiple. Analyst Commentary Recent Street research on Collegium Pharmaceutical shows a mix of optimism and caution around the updated price targets and earnings outlook into 2026.Narrativ-Update • Feb 10
COLL: Affordable Medicines Focus Will Support Constructive 2026 Outlook Upside
Narrative Update on Collegium Pharmaceutical Analysts have kept their fair value estimate for Collegium Pharmaceutical steady at about $53.17 per share, with modest model tweaks around discount rate and future P/E, reflecting recent price target adjustments to $55 and $56 tied to updated 2026 outlooks and an ongoing focus on affordable medicines. Analyst Commentary Recent research updates point to a fairly constructive stance on Collegium Pharmaceutical, with price targets clustered in the mid US$50s and models now aligned with the initial 2026 outlook and an emphasis on affordable medicines.Narrativ-Update • Jan 25
COLL: 2026 Outlook And Affordable Medicines Theme Will Support Upside Potential
Analysts have trimmed their average price target for Collegium Pharmaceutical to about $55, with adjustments clustered around US$55 to US$56 as they update models for the company's initial 2026 outlook and lean into the affordable medicines theme. Analyst Commentary Bullish Takeaways Bullish analysts see the updated fiscal 2026 outlook as solid enough to support price targets around US$55 to US$56, which they view as aligned with their current models.Narrativ-Update • Jan 11
COLL: 2026 Earnings Outlook And Affordable Medicines Theme Will Drive Returns
Analysts have raised their fair value estimate for Collegium Pharmaceutical to about $53.17 from $48.67, citing updated price targets around $55 to $56 and revised views on 2026 earnings potential and profitability. Analyst Commentary Recent research on Collegium Pharmaceutical is centered on updated price targets and how the initial 2026 outlook feeds into views on earnings power and profitability.Narrativ-Update • Dec 23
COLL: Higher 2025 Revenue Guidance And Stable Outlook Will Shape Future Returns
Analysts have modestly raised their price target on Collegium Pharmaceutical from approximately $47 to $48.67 per share. This reflects slightly improved fair value estimates supported by stable discount rate assumptions, largely unchanged long term revenue and margin expectations, and a somewhat higher anticipated future earnings multiple.Narrativ-Update • Dec 08
COLL: Steady Outlook And Higher 2025 Revenue Guidance Will Shape Future Returns
Analysts have reiterated their price target for Collegium Pharmaceutical at approximately 46.80 dollars, citing largely unchanged assumptions for the discount rate, revenue trajectory, profit margins, and future valuation multiples that support a stable fair value outlook. What's in the News Collegium Pharmaceutical raised its full year 2025 net product revenue guidance to a range of 775 million to 785 million dollars, up from the prior 745 million to 760 million dollar outlook (company guidance).Narrativ-Update • Nov 24
COLL: Increased Revenue Guidance And Margin Shifts Will Shape Measured Future Returns
Collegium Pharmaceutical’s analyst price target remains unchanged at $46.80, as analysts point to a balanced outlook where revisions to profit margin and future P/E estimates offset each other. What's in the News Collegium Pharmaceutical raised its 2025 net product revenue guidance and now expects a range of $775 to $785 million, up from the previous range of $745 million to $760 million (Key Developments).Analyseartikel • Nov 08
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 28% Jump Shows Its Popularity With Investors
Collegium Pharmaceutical, Inc. ( NASDAQ:COLL ) shares have had a really impressive month, gaining 28% after a shaky...Narrativ-Update • Nov 08
COLL: Higher Margins And Full-Year Guidance Will Support Balanced Future Returns
Analysts have raised their price target for Collegium Pharmaceutical from $44.60 to $46.80. This reflects improved expectations for profit margins even though projected revenue growth is lower.Analyseartikel • Oct 19
We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jul 31
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable
With a price-to-earnings (or "P/E") ratio of 22.5x Collegium Pharmaceutical, Inc. ( NASDAQ:COLL ) may be sending...Analyseartikel • May 16
There May Be Reason For Hope In Collegium Pharmaceutical's (NASDAQ:COLL) Disappointing Earnings
The market was pleased with the recent earnings report from Collegium Pharmaceutical, Inc. ( NASDAQ:COLL ), despite the...Analyseartikel • Apr 07
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Mar 03
Collegium Pharmaceutical: Checking The Boxes
Summary Collegium Pharmaceutical, Inc. reported strong Q4 results last week where the company easily beat on the bottom line and grew revenues north of 20%. The stock is quite cheap on both a P/E basis and a price-to-sales valuation. While the company competes in crowded markets, management is predicting solid growth in revenue and adjusted EBITDA in FY2025. An updated analysis of Collegium Pharmaceutical follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Dec 24
Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet
Collegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) price-to-sales (or "P/S") ratio of 1.6x might make it look like a buy...Seeking Alpha • Nov 26
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Summary Collegium Pharmaceutical’s pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of Jornay PM expands COLL’s portfolio into neurology, tapping into the rapidly growing ADHD market, which is projected to reach $30.6 billion by 2032. Collegium reported strong Q3 2024 results, with 17% YoY revenue growth and EBIT margins improving to 35.2%, showcasing operational efficiency. Still, COLL faces risks, including high financial debt, integration challenges for Jornay PM, and potential revenue concentration in pain management products. Despite this, I believe COLL’s compelling valuation metrics and growth projections indicate upside potential, justifying my "Strong Buy" rating. Read the full article on Seeking AlphaAnalyseartikel • Nov 14
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality
Collegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) earnings announcement last week was disappointing for investors...Analyseartikel • Oct 28
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Neues Narrativ • Sep 15
Ironshore Acquisition And Calculated Moves Set To Propel Growth In ADHD Market
Collegium Pharmaceutical's acquisition of Ironshore Therapeutics positions them in the ADHD market, aiming for revenue growth through diversified offerings and operational efficiencies.Seeking Alpha • Aug 09
Collegium Pharmaceutical: Diversifying And Growing
Summary After its initial success with Xtampza, Collegium has grown and diversified its product line-up. Collegium Pharmaceutical acquired BioDelivery Sciences in 2022, adding BELBUCA to its product portfolio, complicating finances but offering growth potential. The recent acquisition of Ironshore Therapeutics adds another product to Collegium's business, with strong prescription numbers and revenue growth potential. Despite complicated earnings and debt load, Collegium's revenues and adjusted earnings have been steadily increasing, with a solid outlook for 2024. Read the full article on Seeking AlphaAnalyseartikel • Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Collegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) price-to-sales (or "P/S") ratio of 1.9x might make it look like a buy...Analyseartikel • Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • May 13
Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
Summary Collegium Pharmaceutical, Inc. stock fell 16% on Friday after Q1 results missed expectations and a CEO replacement was announced. Despite the negative reaction, there were some positive aspects in the results and guidance. An updated analysis around Collegium Pharmaceuticals is provided in the paragraphs below. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 834 | N/A | 260 | 259 | 3 |
| 12/31/2027 | 886 | 158 | 351 | 360 | 5 |
| 12/31/2026 | 875 | 108 | 315 | 352 | 5 |
| 3/31/2026 | 796 | 75 | 330 | 331 | N/A |
| 12/31/2025 | 781 | 63 | 328 | 329 | N/A |
| 9/30/2025 | 757 | 58 | 289 | 291 | N/A |
| 6/30/2025 | 707 | 36 | 202 | 203 | N/A |
| 3/31/2025 | 664 | 44 | 197 | 198 | N/A |
| 12/31/2024 | 631 | 69 | 203 | 205 | N/A |
| 9/30/2024 | 599 | 89 | 192 | 194 | N/A |
| 6/30/2024 | 577 | 100 | 276 | 277 | N/A |
| 3/31/2024 | 567 | 93 | 308 | 309 | N/A |
| 12/31/2023 | 567 | 48 | 274 | 275 | N/A |
| 9/30/2023 | 547 | 9 | 266 | 268 | N/A |
| 6/30/2023 | 537 | -11 | 235 | 236 | N/A |
| 3/31/2023 | 525 | -29 | 176 | 177 | N/A |
| 12/31/2022 | 464 | -25 | 123 | 124 | N/A |
| 9/30/2022 | 362 | -43 | 93 | 94 | N/A |
| 6/30/2022 | 314 | -35 | 67 | 69 | N/A |
| 3/31/2022 | 273 | 43 | 56 | 58 | N/A |
| 12/31/2021 | 277 | 72 | 102 | 104 | N/A |
| 9/30/2021 | 326 | 104 | 87 | 90 | N/A |
| 6/30/2021 | 326 | 107 | 102 | 107 | N/A |
| 3/31/2021 | 321 | 42 | 115 | 121 | N/A |
| 12/31/2020 | 310 | 27 | -280 | 94 | N/A |
| 9/30/2020 | 308 | 18 | -286 | 87 | N/A |
| 6/30/2020 | 302 | 0 | -313 | 59 | N/A |
| 3/31/2020 | 299 | -13 | -341 | 30 | N/A |
| 12/31/2019 | 297 | -23 | N/A | 28 | N/A |
| 9/30/2019 | 296 | -11 | N/A | 54 | N/A |
| 6/30/2019 | 293 | -22 | N/A | 90 | N/A |
| 3/31/2019 | 291 | -30 | N/A | 131 | N/A |
| 12/31/2018 | 280 | -39 | N/A | 169 | N/A |
| 9/30/2018 | 218 | -66 | N/A | 114 | N/A |
| 6/30/2018 | 160 | -62 | N/A | 59 | N/A |
| 3/31/2018 | 90 | -70 | N/A | -14 | N/A |
| 12/31/2017 | 28 | -75 | N/A | -67 | N/A |
| 9/30/2017 | 19 | -85 | N/A | -77 | N/A |
| 6/30/2017 | 7 | -98 | N/A | -84 | N/A |
| 3/31/2017 | 4 | -102 | N/A | -87 | N/A |
| 12/31/2016 | 2 | -94 | N/A | -75 | N/A |
| 9/30/2016 | 0 | -76 | N/A | -61 | N/A |
| 6/30/2016 | N/A | -59 | N/A | -48 | N/A |
| 3/31/2016 | N/A | -40 | N/A | -31 | N/A |
| 12/31/2015 | N/A | -20 | N/A | -22 | N/A |
| 9/30/2015 | N/A | -15 | N/A | -20 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: COLLDas prognostizierte Gewinnwachstum (41.9% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: COLLDie Erträge des Unternehmens (41.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (16.8% pro Jahr).
Hohe Wachstumserträge: COLLEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: COLLDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: COLLDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von COLL in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/18 08:55 |
| Aktienkurs zum Tagesende | 2026/05/18 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Collegium Pharmaceutical, Inc. wird von 13 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jenna Davidner | Barclays |
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |
| Dana Flanders | Guggenheim Securities, LLC |